Canada will explore new methods to prevent, prepare for and respond to biological threats with a new research contract awarded to ImmunoVaccine Technologies (IVT).
The three-year research agreement was awarded by Defence Research and Development Canada (DRDC).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The contract includes the preclinical application of the company’s DepoVax vaccine for anthrax antigens.
IVT vice president of R&D Dr Marc Mansour said that DepoVax is a very appropriate anti-anthrax vaccine because of the lengthy immunity it provides.
“Dr Les Nagata and his research team at DRDC are leaders in developing vaccines to fight deadly microbial pathogens and we look forward to this collaboration,” Mansour said.
“Because our DepoVax formulation creates a long-lasting immune response and comes in a dry format that is easily reconstituted, it is well suited for the development of an effective anti-anthrax vaccine.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataInfection with anthrax is potentially life-threatening and caused by a spore-forming bacterium, bacillus anthracis.
